CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Fermata uses computer vision to detect diseases and pests in plants

From TechCrunch

By Rebecca Szkutak

January 7, 2025

Fermata uses computer vision to detect diseases and pests in plants

Fermata uses computer vision to detect diseases and pests in plants

When Valeria Kogan started her Ph.D. program in bioinformatics, the scientific field that uses computation and software to analyze biological data, in 2017, she imagined her career would always be within the fields of mathematics, medicine, or biology. But after the first AI boom in the late 2010s, she got an intriguing opportunity in a sector she hadn’t considered: agriculture.

Kogan (pictured above in the middle) told TechCrunch that when she was approached by a friend of a friend, a tomato grower looking for someone who understood AI and could help apply the tech to agriculture, she was intrigued. When she heard that they were looking to use AI to monitor plant health, she realized a lot of her bioinformatic background was transferrable.

“When they started sharing with me the challenges they had, plants have health and their health is important, and how they monitor the health of plants, it was clear that technically the challenge is very similar,” Kogan said. “You want to see and make the diagnosis as fast as you can.”

She decided to launch Fermata in 2020. The Tel Aviv- based startup uses computer vision and AI to monitor and diagnose greenhouse crops with diseases or pests. Fermata’s software works with any off-the-shelf camera and takes pictures of a greenhouse’s crops twice a day. Its inhouse AI model analyzes the pictures and sends alerts of infestation or disease to farmers through an app.

Kogan acknowledged that companies looking to bring AI to farms have struggled to gain meaningful traction in the past. While she doesn’t think her company has garnered meaningful market share just yet, she thinks Fermata’s approach has allowed the team to gain traction for a few reasons.

For one, she said, they approached the market with genuine curiosity, looking to find out what greenhouse farms needed, as opposed to trying to sell them tech they didn’t want.

“The original idea that I had was let’s build the robots that will be moving through the greenhouse, and we even built the first project,” Kogan said. “We did the first mistake, we built things before talking to anybody, and it still sits in my dad’s garage. When we started talking to people, it was very clear that no one needs that, the robot is a bad idea.”

She added that their approach to training their AI model has likely also helped them stand out. Since the beginning, Fermata has kept its data labeling team in-house, as opposed to outsourcing it, which Kogan attributes the company’s accuracy to. When they started, they used publicly-available data, but now they train their models on their customers’ data and have a research and development center where they infect plants with different diseases too.

“We love customers who have a lot of problems because it brings us a lot of data, especially if they have some deadly diseases,” Kogan said, followed by a laugh. “We’re like, okay, let’s look serious on the call, and that we’re worried because that is bad news for them but for us it’s amazing news.”

When Fermata launched, Kogan said they thought it would make sense to partner with companies that were already selling to farms. That approach didn’t garner a lot of call backs when Fermata started it in 2020, but when AI started gaining momentum in 2022 that changed. Now, Fermata works directly with farms but also partners with large agriculture enterprises like Bayer and Syngenta. The company declined to share growth metrics but has deployed more than 100 cameras.

Fermata also recently raised a $10 million Series A round. The $10 million came entirely from Raw Ventures, a European VC. The firm was an existing investor and Kogan said when they set out to raise this current round, they didn’t feel the need to dilute the cap table with more investors.

The round will be used to help the company scale and to reach its goal of being profitable by 2026. Kogan said that they’ve been able to grow thus far without a sales team, and largely from inbound interest, but are looking to bulk up their sales team. Fermata currently just works with greenhouse-grown tomatoes but is actively working toward expanding into new crops and growing its partnerships.

View original article on techcrunch.com

Most Recent

Amazon is taking its biggest shot at Nvidia yet with new TorchNeuron dev tool

Amazon wants to break Nvidia’s hold on PyTorch, the free toolkit used to build most AI apps, so that more developers run their apps on alternative chips like its own.

Oct 19, 2026

Replika’s founder built the AI assistant she pitched at Disrupt 12 years ago

Eugenia Kuyda's newest startup Wabi is positioned to take advantage of an idea she had more than a decade ago. Wabi offers a personal AI assistant with a twist, free and downloadable to anyone today.

Oct 19, 2026

AI assistant startup Town nabs unicorn valuation 4 months after launch

AI assistant startup Town nabbed a unicorn valuation on Monday, announcing a $108 million Series B round co-led by Forerunner Ventures and Menlo Ventures.

Oct 19, 2026

Khosla Ventures doubles down on Even Healthcare to challenge India’s hospital economics

Even Healthcare reaches a $300 million valuation in a Khosla Ventures-led round as it plans to expand its hospital network in India.

Oct 19, 2026

Similar Posts

AI isn’t close to curing cancer. This startup says it knows what it will take.

It's the data, stupid.

Aug 19, 2026

Grove cuts clinical trial enrollment time with AI

Tran Le was an engineering student at Stanford University when she tried to enroll in a clinical trial for her chronic condition. Although she identified several promising trials, she found the sign-up process daunting — she had to have extensive email exchanges with clinical sites and complete lengthy 20-page forms. All that paperwork was so cumbersome, Le saw an opportunity to use generative AI to reduce the time it takes to get started with a trial from weeks to minutes. Last year, she teame

Jan 8, 2025

Cohere co-founder Nick Frosst thinks everyone needs to be more realistic about what AI can and cannot do

AI companies are gobbling up investor money and securing sky-high valuations early in their life cycle. This dynamic has many calling the AI industry a bubble. Nick Frosst, a co-founder of Cohere, which builds custom AI models for enterprise customers, recently said on TechCrunch’s Found podcast that he doesn’t think the AI industry is in a bubble. While he acknowledges the froth, he thinks calling it a bubble discredits the companies, like his own Cohere, that are creating genuinely useful fea

Aug 8, 2024

YC-backed Four Growers builds robots to help solve greenhouse labor shortages

When Brandon Contino and co-founder Dan Chi were developing Four Growers’ produce-harvesting robots, they practically lived in a greenhouse for an entire year. They coded at a small desk tucked in the back corner and discovered that fertilizer bags can be comfortable beds. “We actually started just running everything off a laptop, and I would be there in the row coding. [Chi] would be making changes mechanically,” Contino, now CEO, told TechCrunch. “We’d run it then we’d make code changes, we’d

Nov 20, 2024